Products
Betifisolimab Biosimilar Monoclonal Antibody (PD-L1) for Research
Cat No.: GMP-Bios-INN-1102
Anti-PDL1/CD274 therapeutic antibody (Pre-made Betifisolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Betifisolimab (development code MSB-2311) is a monoclonal antibody targeting PD-L1 (CD274). It is developed by MabSpace Biosciences and Transcenta Holding for solid tumours. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1102-1mg | 1mg | 3090 |
| GMP-Bios-INN-1102-10mg | 10mg | |
| GMP-Bios-INN-1102-100mg | 100mg | |
| GMP-Bios-INN-1102-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Betifisolimab biosimilar, Whole mAb, Anti-PDL1/CD274 Antibody: Anti-PD-L1/CD274/Programmed cell death 1 ligand 1/PDCD1 ligand 1 therapeutic antibody |
| INN Name | Betifisolimab |
| Target | PDL1/CD274 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | MabSpace Biosciences;Transcenta Holding |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | Haematological malignancies |
| Production | na |
| Development Tech | na |
